Hsbc Holdings PLC Nuvation Bio Inc. Transaction History

Hsbc Holdings PLC

$168 Billion
Q3 2024

A detailed history of Hsbc Holdings PLC transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Hsbc Holdings PLC holds 117,353 shares of NUVB stock, worth $328,588. This represents 0.0% of its overall portfolio holdings.

Number of Shares

117,353

Previous 133,308 11.97%

Holding current value

$328,588

Previous $389,000 30.85%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$2.3 - $3.83 $36,696 - $61,107	-15,955 Reduced 11.97%	117,353 $269,000
Q2 2024 Aug 12, 2024	SELL	$2.58 - $3.69 $150,241 - $214,879	-58,233 Reduced 30.4%	133,308 $389,000
Q1 2024 May 15, 2024	BUY	$1.46 - $3.97 $24,231 - $65,890	16,597 Added 9.49%	191,541 $697,000
Q4 2023 Feb 12, 2024	BUY	$0.96 - $1.53 $112 - $179	117 Added 0.07%	174,944 $264,000
Q3 2023 Nov 13, 2023	BUY	$1.26 - $2.1 $79,183 - $131,972	62,844 Added 56.12%	174,827 $234,000
Q2 2023 Aug 11, 2023	BUY	$1.56 - $1.84 $19,562 - $23,073	12,540 Added 12.61%	111,983 $201,000
Q1 2023 May 15, 2023	BUY	$1.6 - $2.48 $27,860 - $43,184	17,413 Added 21.23%	99,443 $165,000
Q4 2022 Feb 14, 2023	BUY	$1.68 - $2.5 $90,620 - $134,852	53,941 Added 192.04%	82,030 $157,000
Q3 2022 Nov 14, 2022	BUY	$0.29 - $4.04 $8,145 - $113,479	28,089 New	28,089 $66,000
Q3 2021 Nov 12, 2021	SELL	$7.78 - $10.0 $82,366 - $105,870	-10,587 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$9.22 - $14.48 $97,612 - $153,299	10,587 New	10,587 $98,000

Others Institutions Holding NUVB

# of Institutions

159

Shares Held

157M

Call Options Held

3.2K

Put Options Held

98.7K

View Full List

About Nuvation Bio Inc.

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $608M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

More about NUVB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.

Account

Hsbc Holdings PLC Nuvation Bio Inc. Transaction History